MAK Capital is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $2.0 billion in regulatory assets under management. Its private funds, of all types, hold $2.0 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated -0.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +26.3% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $2.0 billionForm ADV Item 5.F
- Gross assets of private funds
- $2.0 billionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- 12Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 158132
- Latest Form ADV
- 03/26/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +22.1% | +14.8% |
| Q1 2026 | -18.7% | -4.6% |
| Q4 2025 | +11.3% | +2.4% |
| Q3 2025 | +5.0% | +7.8% |
| Q2 2025 | -7.4% | +10.4% |
| Q1 2025 | -12.4% | -4.5% |
| Q4 2024 | +8.0% | +2.1% |
| Q3 2024 | +24.4% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- Agilysys Inc Com$124.6 million
- Grupo Financiero Galicia S.A$74.3 million
- Acadia Healthcare Company In$71.8 million
- Uniqure$56.7 million
- Champion Homes Inc$55.7 million
- Autolus Therapeutics PLC$53.8 million
- Clearpoint Neuro Inc$42.4 million
- Grupo Supervielle S.A.$41.1 million
- Caris Life Sciences Inc$34.5 million
- Annexon Inc$33.5 million
As of 2026-06-30, from 13F filing by MAK Capital One LLC.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures